Media coverage about Sientra (NASDAQ:SIEN) has trended positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sientra earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 47.9274147608834 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- New Report Says Allergen, Inc, Gc Aesthetics Plc,Sientra, Inc. Will Drive The Breast Implant Market – Facts of Week (factsweek.com)
- Edited Transcript of SIEN earnings conference call or presentation 13-Mar-18 8:30pm GMT (finance.yahoo.com)
- Zacks Investment Research Upgrades Sientra (SIEN) to Buy (americanbankingnews.com)
- Sientra (SIEN) Upgraded to Hold by ValuEngine (americanbankingnews.com)
- Sientra (SIEN) Downgraded by Zacks Investment Research (americanbankingnews.com)
SIEN has been the topic of a number of recent research reports. William Blair reaffirmed a “buy” rating on shares of Sientra in a report on Thursday, March 1st. Stifel Nicolaus upgraded shares of Sientra from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Friday, January 19th. Canaccord Genuity reiterated a “buy” rating and issued a $19.00 price objective on shares of Sientra in a research report on Friday, January 5th. Zacks Investment Research upgraded shares of Sientra from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Thursday, March 15th. Finally, ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. Sientra presently has an average rating of “Hold” and a consensus target price of $13.20.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, March 13th. The medical instruments supplier reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.21). Sientra had a negative return on equity of 107.35% and a negative net margin of 175.22%. The company had revenue of $11.10 million for the quarter, compared to analysts’ expectations of $11.90 million. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. Sientra’s revenue for the quarter was up 70.8% on a year-over-year basis. equities analysts anticipate that Sientra will post -2.68 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://baseballnewssource.com/2018/03/21/sientra-sien-getting-favorable-press-coverage-study-shows/2029458.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.